The Open Clinical Trail Of Aripiprazole Improve Early Onset Schizophrenia With Metabolic Disorders

Objective: There are little researches on treatment of early onset schizophrenia(EOS)with metabolic disorder.We plan to switch to aripiprazole for improving metabolic parameters of EOS,and explores effect to metabolism.Method: Patients were selected who were diagnoised with EOS(age ?18)and treated with any SGAs with the exception of aripiprazole,and whose weight increased ?7% after 8 weeks,and randomly into the switch group(N=70)and control group(N=73).SGAs in the switch group were gradually replaced by aripiprazole,the control group maintain the original drug,the research observation is last to 52 weeks.All the patients followed a healty lifestyle education(HLE).Metabolic parameters were measured at baseline and weeks 24 and 52,including weight,body mass index(BMI),waist circumference(WC),fasting plasma glucose(FPG),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL),high-density lipoprotein(HDL),blood pressure(BP)etc.Results: At the 52 weekends the analysis included 50 switchers and 54 stayers,The results were as follows:1.In the control group weight,BMI and WC were increased,while the switch group decreased.The average difference between groups was significant,that of weight was 14.30kg(P<0.0001),BMI 6.63 kg/m2(P<0.0001),and WC 11.9cm(P<0.001)respectively.2.In the control group TG,HDL and TC were all elevated,while the switch group decreased.The most significant average difference between groups was: HDL5.44mmol/L(P<0.001),TC 6.05mmol/L(P<0.0001),Non-HDL 0.61mmol/L(P<0.01)and TG 0.47mmol/L(P<0.01)respectively.3.All the deduction rate of PANSS and CGI-SI scale score were decreased and were statistically significant(P<0.01)in two groups.There was no significant difference between groups(P >0.05).Conclusion: In the control group where the original SGAs were continued to treat EOS,TC and TG were all significantly increased,and the incidence of EOS withoverweight and obesity was increased from baseline 33.3% to 48.9% 1 years later.while their weight decreased after switching into aripiprazole in the switch group,and TC,TG and the incidence of overweight and obesity was decreased 1 years later.Clinical symptoms relieved in both groups,it is feasible to improve metabolic parameters of switching other SGAs to aripiprazole in EOS with metabolic disorder.